← Back to Search

GLP-1 Receptor Agonist

Retatrutide for Type 2 Diabetes

Phase 3
Recruiting
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Pivotal Trial

Summary

This trial aims to see if retatrutide is better than a placebo for treating Type 2 Diabetes in patients with poor blood sugar control. It will last around 11 months and participants may need

Who is the study for?
This trial is for adults with Type 2 Diabetes who haven't been able to control their blood sugar levels through diet and exercise alone. Participants should be committed to the study duration of about 11 months and up to 11 visits.
What is being tested?
The trial is testing the effectiveness and safety of a new medication called Retatrutide compared to a placebo, which has no active ingredients, in managing blood sugar levels in people with Type 2 Diabetes.
What are the potential side effects?
Potential side effects of Retatrutide are not specified here but may include reactions similar to other diabetes medications such as low blood sugar, nausea, digestive issues, or allergic responses.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: Retatrutide Dose Level 3Experimental Treatment1 Intervention
Participants will receive retatrutide administered SC.
Group II: Retatrutide Dose Level 2Experimental Treatment1 Intervention
Participants will receive retatrutide administered SC.
Group III: Retatrutide Dose Level 1Experimental Treatment1 Intervention
Participants will receive retatrutide administered subcutaneously (SC).
Group IV: PlaceboPlacebo Group1 Intervention
Participants will receive placebo administered SC.

Find a Location

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,680 Previous Clinical Trials
3,465,904 Total Patients Enrolled
11 Trials studying Diabetes
15,748 Patients Enrolled for Diabetes
Study DirectorEli Lilly and Company
1,391 Previous Clinical Trials
428,361 Total Patients Enrolled
3 Trials studying Diabetes
4,457 Patients Enrolled for Diabetes
~320 spots leftby Jun 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top